Impact of relative humidity and collection media on mycobacteriophage D29 aerosol

Applied and Environmental Microbiology

Volumn 78, Issue 5, 2012, Pages 1466-1472

  Liu, Keyang ^a   Wen, Zhanbo ^a   Li, Na ^a   Yang, Wenhui ^a   Wang, Jie ^a   Hu, Lingfei ^a   Dong, Xiaokai ^a   Lu, Jianchun ^a   Li, Jinsong ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL GENERATION; BIOAEROSOLS; COLLECTION EFFICIENCY; CULTURABILITY; DETECTION METHODS; LOW HUMIDITY; MYCOBACTERIOPHAGE; MYCOBACTERIUM TUBERCULOSIS; PHOSPHATE-BUFFERED SALINES; POTENTIAL TOOL; REAL-TIME PCR; SAMPLING SYSTEMS; SPRAY LIQUIDS; STORAGE CONDITION; STORAGE TEMPERATURES; SUSPENSION MEDIUM; TEST CHAMBERS;

ATMOSPHERIC AEROSOLS; ATMOSPHERIC HUMIDITY; NUTRIENTS; POLYMERASE CHAIN REACTION; SALINE WATER; TUBES (COMPONENTS);

DEIONIZED WATER;

AEROSOL; BACTERIOPHAGE; BACTERIUM; DETECTION METHOD; DISEASE TREATMENT; PHOSPHATE; POLYMERASE CHAIN REACTION; REAL TIME; RELATIVE HUMIDITY; SAMPLING;

AEROSOL; ARTICLE; HUMIDITY; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; METHODOLOGY; MICROBIAL VIABILITY; MYCOBACTERIOPHAGE; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; VIROLOGY;

AEROSOLS; HUMIDITY; MICROBIAL VIABILITY; MYCOBACTERIOPHAGES; MYCOBACTERIUM TUBERCULOSIS; SPECIMEN HANDLING;

ANIMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 84863134374     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.06610-11     Document Type: Article

References (70)

1. Adams MH. 1959. Bacteriophages, p 450-456. Interscience Publishers, Inc., New York, NY.
2. Alvarez AJ, Buttner MP, Stetzenbach LD. 1995. PCR for bioaerosol monitoring, sensitivity and environmental interference. Appl. Environ. Microbiol. 61:3639-3644.
3. Biswas B, et al. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 1:204-210.
4. Broxmeyer L, et al. 2002. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent Mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J. Infect. Dis. 186:1155-1160.
5. Carlton RM. 1999. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Ex. 47:267-274.
6. Carmody LA, et al. 2010. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201:264-271.
7. Chanishvili N, Chanishvili T, Tediashvili M, Barrow PA. 2001. Phages and their application against drug-resistant bacteria. J. Chem. Technol. Biotechnol. 76:689-699.
8. Chauca JA, Palomino JC, Guerra H. 2007. Evaluation of rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis by a mycobacteriophage D29-based assay. J. Med. Microbiol. 56:360-364.
9. Da Silva PA, et al. 2006. Comparison of redox and D29 phage methods for detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 12:293-296.
10. Debarbieux L, et al. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201:1096-1104.
11. de la Iglesia AI, Stella EJ, Morbidoni HR. 2008. Comparison of the performance of two in-house rapid methods for anti-tubercular drug susceptibility testing. Antimicrob. Agents Chemother. 53:808-810.
12. d'Herelle F. 1926. The bacteriophage and its behavior. The Williams & Wilkins Co, Baltimore, MD.
13. Doocy SC, Todd CS, Liainez YB, Ahmadzai A, Burnham GB. 2008. Population based tuberculin skin testing and prevalence of tuberculosis infection in Afghanistan. World Health Population 10:44-53.
14. Dungan RS, Leytem AB. 2009. Qualitative and quantitative methodologies for determination of airborne microorganisms at concentrated animal-feeding operations. World J. Microbiol. Biotechnol. 25:1505-1518.
15. Forade KK, Myers EA, Hanley JT, Ensor DS, Roessler PF. 1999. Methodology to perform clean air delivery rate type determinations with microbiological aerosols. Aerosol Sci. Technol. 30:235-245.
16. Gali N, et al. 2003. Utility of an in-house mycobacteriophage-based assay for rapid detection of rifampin resistance in Mycobacterium tuberculosis clinical isolates. J. Clin. Microbiol. 41:2647-2649.
17. Gali N, et al. 2006. Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance. J. Clin. Microbiol. 44:201-205.
18. Geier M, Frigg ME, Merril C. 1973. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246:221-222.
19. Gorski A, et al. 2009. Bacteriophage therapy for the treatment of infections. Curr. Opin. Invest. Drugs 10:766-774.
20. Harstad JB. 1965. Sampling submicron T1 bacteriophage aerosols. J. Appl. Microbiol. 13:99-908.
21. Hatch MT, Warren JC. 1969. Enhanced recovery of airborne T3 coliphage and Pasteurella pestis bacteriophage by means of a presampling humidification technique. J. Appl. Microbiol. 17:685-689.
22. Hatfull GF, et al. 2010. Comparative genomic analysis of 60 mycobacteriophage genomes: genome clustering, gene acquisition, and gene size. J. Mol. Biol. 397:119-143.
23. Hauduroy P, Rosset W. 1963. Tentative de traitement des hamsters inocules avec le BCG par un bacteriophage. Ann. Inst. Pasteur 104:419-420.
24. Heidelberg JF, et al. 1997. Effect of aerosolization on culturability and viability of gram-negative bacteria. Appl. Environ. Microbiol. 63:3585-3588.
25. Ho K. 2001. Bacteriophage therapy for bacterial infections: rekindling a memory from the pre-antibiotics era. Perspect. Biol. Med. 44:1-16.
26. Hogan CJ, Jr, et al. 2005. Sampling methodologies and dosage assessment techniques for submicrometre and ultrafine virus aerosol particles. J. Appl. Microbiol. 99:1422-1434.
27. Ijaz MK, et al. 1994. Studies on the survival of aerosolized bovine rotavirus (UK) and a murine rotavirus. Comp. Immunol. Microbiol. Infect. Dis. 17:91-98.
28. Kim SW, Ramakrishnan MA, Raynor PC, Goyal SM. 2007. Effects of humidity and other factors on the generation and sampling of a coronavirus aerosol. Aerobiologia 23:239-248.
29. Kutateladze M, Adamia R. 2008. Phage therapy experience at the Eliava Institute. Med. Maladies Infect. 38:426-430.
30. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28:591-595.
31. Lin XJ, et al. 2000. Survival of airborne microorganisms during swirling aerosol collection. Aerosol Sci. Technol. 32:184-196.
32. Lu JC. 2004. Generation of bioaerosol, p 589-591 In Che FX, Li JS, Cai TJ (ed), The theory and apply of aerobiology. Science Press, Beijing, China.
33. Mankiewicz E, Beland J. 1964. The role of mycobacteriophages and of cortisone in experimental tuberculosis and sarcoidosis. Am. Rev. Respir. Dis. 89:707-720.
34. May KR. 1973. The Collison nebulizer: description, performance and application. J. Aerosol Sci. 4:235-243.
35. McNerney R. 1999. TB: the return of the phage. A review of fifty years of mycobacteriophage research. Int. J. Tuberc. Lung D 3:179-184.
36. McNerney R. 2002. Phage tests for diagnosis and drug susceptibility testing. Int. J. Tuberc. Lung D 6:1129-1130.
37. McNerney R, Kambashi BS, Kinkese J, Tembwe R, Godfrey-Faussett P. 2004. Development of a bacteriophage phage replication assay for diagnosis of pulmonary tuberculosis. J. Clin. Microbiol. 42:2115-2120.
38. McNerney R, Traore H. 2005. Mycobacteriophage and their application to disease control. J. Appl. Microbiol. 99:223-233.
39. McNerney R, Mallard K, Urassa HM, Lemma E, Donoghue HD. 2007. Colorimetric phage-based assay for detection of rifampin-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 45:1330-1332.
40. Menache M, Miller F, Raabe O. 1995. Particle inhalability curves for humans and small laboratory animals. Ann. Occup. Hyg. 39:317-328.
41. Merril CR, et al. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U. S. A. 93:3188-3192.
42. Michael EF, Sarkis GJ, Belanger AE, Hendrix RW, Hatfull GF. 1998. Genome structure of mycobacteriophage D29: implications for phage evolution. J. Mol. Biol. 279:143-164.
43. Misra A, et al. 2011. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 91:71-81.
44. Nevalainen A, Pastuszka J, Liebhaber F, Willeke K. 1992. Performance of bioaerosol samplers: collection characteristics and sampler design considerations, Atmos. Environ. 26A:531-540.
45. Oliveira A, Sereno R, Nicolau A, Azeredo J. 2009. The influence of the mode of administration in the dissemination of three coliphages in chickens. Poultry Sci. 88:728-733.
46. Oliveira A, Sereno R, Azeredo J. 2010. In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet. Microbiol. 146:303-308.
47. Peng L, Chen BW, Luo YA, Wang GZ. 2006. Effect of mycobacteriophage to intracellular mycobacteria in vitro. Chin. Med. J. 119:692-695.
48. Rabbe OG, Al-Bayati MA, Teague SV, Rasolt A. 1988. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann. Occup. Hyg. 32:53-63.
49. Rule AM, Schwab KJ, Kesavan J, Buckley TJ. 2009. Assessment of bioaerosol generation and sampling efficiency based on Pantoea agglomerans. Aerosol Sci. Tech. 43:620-628.
50. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
51. Sattar SA, Ijaz MK, Johnson-Lussenburg CM, Springthorpe VS. 1984. Effect of relative humidity on the airborne survival of rotavirus SA11. Appl. Environ. Microbiol. 47:879-881.
52. Schlesinger RB. 1985. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J. Toxicol. Environ. Health 15:197-214.
53. Shahamat M, et al. 1997. Evaluation of media for recovery of aerosolized bacteria. Aerobiologia 13:219-226.
54. Sharp R. 2001. Bacteriophages: biology and history. J. Chem. Technol. Biotechnol. 76:667-672.
55. Simboli N, et al. 2005. In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings. Antimicrob. Agents Chemother. 49:425-427.
56. Sulakvelidze A, Kutter E. 2005. Bacteriophage therapy in humans, p 381-436 In Kutter E, Sulakvelidze A (ed), Bacteriophages: biology and applications. CRC Press, Boca Raton, FL.
57. Sula L, Sulova J, Stolcpartova M. 1981. Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech. Med. 4:209-214.
58. Summers WC. 2001. Bacteriophage therapy. Annu. Rev. Microbiol. 55: 437-451.
59. Thomas RJ, et al. 2008. Characterization and deposition of respirable large- and small-particle bioaerosols. Appl. Environ. Microbiol. 74:6437-6443.
60. Thorne PS, Kiekhaefer MS, Whitten P, Donham KJ. 1992. Comparison of bioaerosol sampling methods in barns housing swine. Appl. Environ. Microbiol. 58:2543-2551.
61. Tseng CC, Li CS. 2005. Collection efficiencies of aerosol samplers for virus-containing aerosols. J. Aerosol Sci. 36:593-607.
62. Verreault D, Moineau S, Duchaine C. 2008. Methods for sampling of airborne virus. Microbiol. Mol. Biol. R 72:413-444.
63. Wen ZB, et al. 2009. Detection of viral aerosols by use of real-time quantitative PCR. Aerobiologia 25:65-73.
64. Westwater C, et al. 2003. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47:1301-1307.
65. Willeke K, Lin XJ, Grinshpun SA. 1998. Improved aerosol collection by combined impaction and centrifugal motion. Aerosol Sci. Technol. 28: 439-456.
66. World Health Organization. 2009. Global tuberculosis control: a short update to the 2009 report. World Health Organization, Geneva, Switzerland.
67. World Health Organization. 2010. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. World Health Organization, Geneva, Switzerland.
68. Yu L, et al. 2009. Effects of different sampling solutions on the survival of bacteriophages in bubbling aeration. Aerobiologia doi:10.1007/s10453-009-9144-4.
69. Yzquierdo SL, et al. 2006. Evaluation of phage assay for rapid phenotypic detection of rifampicin resistance in Mycobacterium tuberculosis. Ann. Clin. Microbiol. Antimicrob. 5:11.
70. Zemskova ZS, Dorozhkova IR. 1991. Pathomorphological assessment of the therapeutic effect of mycobacteriophages in tuberculosis. Probl. Tuberk. 11:63-66.